People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Biodexa Pharmaceuticals Plc | — | Pharmaceuticals | Series A | $27.1M | $25.3M | 2023 |
Dmitry Zamoryakhin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Dmitry Zamoryakhin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Stephen Stamp | 1 | 1 |
| Simon Turton | 1 | 1 |
| Stephen Parker | 1 | 1 |
| Sijmen De Vries | 1 | 1 |
| Ann Merchant | 1 | 1 |
| DMITRY B. ZAMORYAKHIN | 1 | 1 |
| STEPHEN B. PARKER | 1 | 1 |
| SIJMEN B. DE VRIES | 1 | 1 |
| Rolf Stahel | 1 | 1 |
| Craig Cook | 1 | 1 |
| Frederic Duchesne | 1 | 1 |
| Huaizheng Peng | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.